Pre‐Treatment With Potassium Iodide and Higher Radioiodine Dose Are the Risk Factors of Mid‐to‐Late‐Phase Transient Thyrotoxicosis Following Radioiodine Therapy for Graves' Disease in Japanese Patients: A Retrospective Cohort Study
A higher <sup>131</sup>I dose was an independent risk factor for mid-to-late-phase transient thyrotoxicosis after RIT. Higher pre-RIT FT3 levels and KI use may contribute to this risk. Identifying patients with these factors may be helpful for closer post-RIT monitoring to prevent complications and avoid misdiagnosing this transient event as a treatment failure.
Authors
- Kazushi Maruo (ORCID: https://orcid.org/0000-0002-3093-0386)
- Yoshinori Osaki (ORCID: https://orcid.org/0000-0003-1425-7790)
- Yuki Murayama (ORCID: https://orcid.org/0000-0003-2264-3616)
- Motohiro Sekiya
- R Nakajima
- Hiroshi Fukazawa
- Yoko Sugano
- Erika Matsuda (ORCID: https://orcid.org/0000-0002-9465-3007)
- Hitoshi Iwasaki (ORCID: https://orcid.org/0000-0001-8081-6226)
- Hitoshi Shimano
- Takaaki Matsuda
Institutions
- University of Tsukuba (JP)
- Mito Saiseikai General Hospital (JP)
- National Hospital Organization Mito Medical Center (JP)
Publication Details
- Journal
- Clinical Endocrinology
- Published
- 2026-01-05
- DOI
- https://doi.org/10.1111/cen.70093
- Primary Topic
- Thyroid Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Tsukuba